Role of Platelet Mass Index in the Differential Diagnosis of Patients with Elevated Prostate-Specific Antigen Levels

Öz

Aim: To evaluate the role of platelet mass index (PMI) calculated using hemogram parameters obtained from a routine blood test in the differentiation of prostate cancer in patients with prostate-specific antigen (PSA) values of 2.5-10 ng/dl.
Material and Method: Seventy-five patients with prostate cancer and 48 with prostatitis were included in the study and grouped according to their pathology results. The white blood cell (WBC), hemoglobin (HGB), thrombocyte (PLT), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV) and PMI values were compared between the two groups.
Results: The PMI and PLT levels of the prostate cancer group were statistically significantly lower than those of the prostatitis group (p<0.05). In predicting prostate cancer, the cut-off value for the PMI level was determined as 1.480, at which the likelihood ratio was calculated as 1.08.
Conclusion: We consider that PMI calculated using hemogram parameters in patients with a PSA value below 10 ng/dl will guide the clinician in differentiating prostate cancer from other prostate pathologies without performing an unnecessary biopsy.

Anahtar Kelimeler

• prostate specific antigen
• platelet mass index
• prostate cancer

Kaynakça

1. 1- Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407
2. 2- Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33:465
3. 3- Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;4:618-629
4. 4- Cihan YB, Arslan A, Ergul MA. Subtypes of White blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. AsianPac J CancerPrev. 2013;14(8):4779-83